Giampaolo Bianchini· @BianchiniGP · X·· 1 天前评分70
正文 · 机器翻译
🔥 FOURLIGHT-1 证实了 atirmociclib 在 CDK4/6i 治疗后的疗效
⚠️ II 期试验：目前尚不足以改变临床实践
👉 这些结果进一步增强了预期：atirmociclib 的疗效可能优于其他 CDK4/6i
➡️ 热切期待 FOURLIGHT-3 的结果
祝贺我的朋友 @antgiorda
#ESMO26
19 浏览 · 0 赞 · 0 转发 · 1 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org帖内回复
- Dr. Robert@robt_heartdoc
@BianchiniGP @antgiorda Kudos to the team. 9.4 vs 6.6 months median PFS post-CDK4/6i deserves attention, though investigator-assessed endpoints in a Phase II warrant caution. I would hold on implications until the Phase III. Look forward to FOURLIGHT-3. #ESMO26
来源：Giampaolo Bianchini · x.com